Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To U.S. Ohm Labs After FDA Crackdown
This article was originally published in The Pink Sheet Daily
Executive Summary
Billings for valacyclovir, generic Valtrex, which Ranbaxy shifted earlier to its New Jersey affiliate, reached $100 million within the first week of the U.S. launch.
You may also be interested in...
Apotex Manufacturing Violations Could Delay Launch Of Taxotere Generic
FDA's warning letter to Apotex for continued manufacturing violations could delay the launch of the company's generic version of the cancer drug Taxotere (docetaxel)
Apotex Manufacturing Violations Could Delay Launch Of Taxotere Generic
FDA's warning letter to Apotex for continued manufacturing violations could delay the launch of the company's generic version of the cancer drug Taxotere (docetaxel)
Ranbaxy Sees Better Days Ahead With The Launch Of Valtrex Generic In U.S.
MUMBAI - There is finally some positive news for India's Ranbaxy as it launched the generic versions of GlaxoSmithKline's herpes treatment Valtrex (valacyclovir) Nov. 25 in the U.S